[go: up one dir, main page]

WO2010041913A3 - Nouvelles utilisations des protéines grs ou de leurs fragments - Google Patents

Nouvelles utilisations des protéines grs ou de leurs fragments Download PDF

Info

Publication number
WO2010041913A3
WO2010041913A3 PCT/KR2009/005829 KR2009005829W WO2010041913A3 WO 2010041913 A3 WO2010041913 A3 WO 2010041913A3 KR 2009005829 W KR2009005829 W KR 2009005829W WO 2010041913 A3 WO2010041913 A3 WO 2010041913A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragments
proteins
grs
grs proteins
novel uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/005829
Other languages
English (en)
Korean (ko)
Other versions
WO2010041913A9 (fr
WO2010041913A2 (fr
Inventor
김성훈
박민철
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Priority to US13/123,522 priority Critical patent/US8901081B2/en
Priority to EP09819420.2A priority patent/EP2351575B1/fr
Publication of WO2010041913A2 publication Critical patent/WO2010041913A2/fr
Publication of WO2010041913A3 publication Critical patent/WO2010041913A3/fr
Publication of WO2010041913A9 publication Critical patent/WO2010041913A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01014—Glycine-tRNA ligase (6.1.1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition anticancer contenant des protéines GRS pleine longueur ou leurs fragments, ou un acide nucléique codant les protéines GRS ou des fragments comme principes actifs. Les protéines GRS ou leurs fragments sont utilisés pour induire de manière spécifique la mort de cellules cancéreuses. Ainsi, la composition de l'invention contenant les protéines GRS ou leurs fragments ou un acide nucléique codant les protéines GRS ou leurs fragments peuvent être utilisés lors d'un traitement anticancer.
PCT/KR2009/005829 2008-10-10 2009-10-12 Nouvelles utilisations des protéines grs ou de leurs fragments Ceased WO2010041913A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/123,522 US8901081B2 (en) 2008-10-10 2009-10-12 Uses of GRS proteins or fragments thereof
EP09819420.2A EP2351575B1 (fr) 2008-10-10 2009-10-12 Grs pour l'utilisation dans le traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0099784 2008-10-10
KR20080099784 2008-10-10

Publications (3)

Publication Number Publication Date
WO2010041913A2 WO2010041913A2 (fr) 2010-04-15
WO2010041913A3 true WO2010041913A3 (fr) 2010-08-05
WO2010041913A9 WO2010041913A9 (fr) 2010-10-07

Family

ID=42101119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005829 Ceased WO2010041913A2 (fr) 2008-10-10 2009-10-12 Nouvelles utilisations des protéines grs ou de leurs fragments

Country Status (4)

Country Link
US (1) US8901081B2 (fr)
EP (1) EP2351575B1 (fr)
KR (1) KR101102485B1 (fr)
WO (1) WO2010041913A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
US9322009B2 (en) 2010-06-01 2016-04-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US9453214B2 (en) 2009-02-27 2016-09-27 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
US9528103B2 (en) 2010-04-27 2016-12-27 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9593323B2 (en) 2010-05-03 2017-03-14 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5771142B2 (ja) * 2008-06-11 2015-08-26 エータイアー ファーマ， インコーポレイテッド チロシル−ｔＲＮＡシンテターゼポリペプチドの血小板新生活性
US8404471B2 (en) 2008-06-26 2013-03-26 Atyr Pharma, Inc. Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
US8404242B2 (en) 2009-03-16 2013-03-26 Atyr Pharma, Inc. Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US20100310576A1 (en) * 2009-03-31 2010-12-09 Adams Ryan A COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
WO2011072266A2 (fr) * 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl-arnt synthétases destinées à moduler l'hématopoïèse
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
ES2638311T3 (es) 2010-04-27 2017-10-19 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, diagnósticas y de anticuerpos relacionadas con fragmentos de proteína de treonil ARNt sintetasas
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ， インコーポレイテッド アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011139907A2 (fr) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Découverte innovatrice de compositions thérapeutiques, diagnostiques, et d'anticorps associées aux fragments protéiques des valyle arnt synthésases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797799C (fr) 2010-05-03 2020-12-08 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps liees a des fragments proteiques de seryle-arnt synthetases
JP6008843B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566499B1 (fr) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
EP2568996B1 (fr) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Compositions thérapeutique, diagnostique et à base d'anticorps contenant des fragments protéiques de phénylalanyl-bêta-arnt synthétases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CA2804416C (fr) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Decouverte innovante de compositions therapeutiques, de diagnostic et d'anticorps se rapportant a des fragments proteiques de glycyl-arnt synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2624857B1 (fr) 2010-10-06 2017-08-02 aTyr Pharma, Inc. Découverte innovante de fragments de protéine de tryptophanyle arnt synthétases associés à des compositions thérapeutiques, diagnostiques et d'anticorps
US9673102B2 (en) * 2011-04-01 2017-06-06 Micron Technology, Inc. Methods of forming vertical field-effect transistor with self-aligned contacts for memory devices with planar periphery/array and intermediate structures formed thereby
WO2012158945A2 (fr) * 2011-05-19 2012-11-22 The Scripps Research Institute Compositions et procédés pour traiter les maladies de charcot-marie-tooth et les maladies neuronales associées
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
KR101398079B1 (ko) * 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
WO2013086228A1 (fr) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Polypeptides aspartyl-arnt synthétase pégylés
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
CA2858613A1 (fr) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Conjugues aspartyl-arnt synthetase-fc
KR101580681B1 (ko) * 2013-02-28 2015-12-29 재단법인 의약바이오컨버젼스연구단 글라이실-tRNA 합성효소를 포함하는 마이크로베지클의 제조방법
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
KR101935372B1 (ko) * 2014-05-28 2019-01-04 재단법인 의약바이오컨버젼스연구단 아미노아실 티알엔에이 합성효소를 포함하는 나노파티클 및 이를 포함하는 항암용 조성물
EP3612215B1 (fr) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions pour le traitement d'inflammation pulmonaire
KR102167755B1 (ko) * 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506607B1 (en) * 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
WO2004038020A1 (fr) * 2002-06-07 2004-05-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genes cibles permettant le diagnostic et le traitement d'un cancer
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
CA2068204C (fr) 1989-11-22 2002-02-12 Arthur Levinson Peptides associes a la latence et leur utilisation
CN1330144A (zh) 2000-06-19 2002-01-09 上海博德基因开发有限公司 一种新的多肽——人I类氨酰基－tRNA合成酶10和编码这种多肽的多核苷酸
JPWO2003051382A1 (ja) 2001-12-14 2005-04-21 株式会社サンドリー アポトーシスを誘導する方法およびそのための組成物
JP5033471B2 (ja) 2007-05-09 2012-09-26 住友化学株式会社 有機化合物の結晶およびその製造方法
US8404471B2 (en) * 2008-06-26 2013-03-26 Atyr Pharma, Inc. Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506607B1 (en) * 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
WO2004038020A1 (fr) * 2002-06-07 2004-05-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genes cibles permettant le diagnostic et le traitement d'un cancer
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SHIBA K ET AL.: "Human glycyl-tRNA synthetase. Wide divergence of primary structure from bacterial counterpart and species-specific aminoacylation.", J BIOL CHEM., vol. 269, no. 47, 25 November 1994 (1994-11-25), pages 30049 - 30055, XP008146986 *
WASENIUS VM ET AL.: "Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.", CLIN CANCER RES., vol. 9, no. 1, January 2003 (2003-01-01), pages 68 - 75, XP008146998 *
WILLIAMS J ET AL.: "Cloning, sequencing and bacterial expression of human glycine tRNA synthetase.", NUCLEIC ACIDS RES., vol. 23, no. 8, 25 April 1995 (1995-04-25), pages 1307 - 1310, XP008147113 *
YANO S ET AL.: "Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.", ONCOL REP., vol. 15, no. 6, June 2006 (2006-06-01), pages 1453 - 1460, XP008146997 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453214B2 (en) 2009-02-27 2016-09-27 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9528103B2 (en) 2010-04-27 2016-12-27 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US9593323B2 (en) 2010-05-03 2017-03-14 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
US9322009B2 (en) 2010-06-01 2016-04-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
EP2351575B1 (fr) 2016-12-14
WO2010041913A9 (fr) 2010-10-07
EP2351575A4 (fr) 2013-04-03
KR101102485B1 (ko) 2012-01-05
US20110256119A1 (en) 2011-10-20
KR20100040697A (ko) 2010-04-20
WO2010041913A2 (fr) 2010-04-15
EP2351575A2 (fr) 2011-08-03
US8901081B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
WO2010041913A3 (fr) Nouvelles utilisations des protéines grs ou de leurs fragments
HK1203077A1 (en) Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013006953A8 (fr) Gènes et protéines pour la synthèse d'alcanoyl-coa
WO2011106766A3 (fr) Protéines modifiées et procédés pour leur production et leur utilisation
WO2013067349A9 (fr) Nouvelle chimie utilisée dans des biocapteurs
WO2011139702A3 (fr) Nucléosides modifiés et composés oligomères préparés à partir de ceux-ci
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
WO2011082270A3 (fr) Composés imidazopyridinyl-aminopyridine substitués
WO2011082273A3 (fr) Composés de pyrroloaminopyrimidine substitués
GB201020995D0 (en) Biological materials and uses thereof
PH12012502272A1 (en) Biological materials related to her3
WO2011082267A3 (fr) Composés triazolo-pyrazine substitués
WO2011079902A3 (fr) Matériaux biologiques et utilisations de ceux-ci
WO2012045082A3 (fr) Synthèse d'acides nucléiques et méthodes d'utilisation associées
MY162737A (en) 4-1bb binding molecules
WO2011082266A3 (fr) Composés hétérocycliques substitués
WO2011135461A3 (fr) Compositions d'argile
WO2009135646A3 (fr) Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
WO2011008495A3 (fr) Formulations d'arginase et procédés
WO2008085221A3 (fr) Utilisation thérapeutique de cellules exprimant cd31
WO2011123678A3 (fr) Composés de benzo-pyrido-triazolo-diazépine substitués
WO2012136898A3 (fr) Nouvelles cutinases, leur préparation et leurs utilisations
WO2009062576A8 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
IN2015DN03206A (fr)
WO2011082268A3 (fr) Composés naphthalényl-pyrimidine substitués

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09819420

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009819420

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009819420

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13123522

Country of ref document: US